MAI Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.2K | Buy |
328
+165
| +101% | +$20.7K | ﹤0.01% | 1860 |
|
|
2025
Q1 | $18K | Sell |
163
-117
| -42% | -$12.9K | ﹤0.01% | 2090 |
|
|
2024
Q4 | $38.2K | Buy |
+280
| New | +$38.2K | ﹤0.01% | 1785 |
|
|
2022
Q3 | – | Sell |
-6,412
| Closed | -$625K | – | 960 |
|
|
2022
Q2 | $625K | Hold |
6,412
| – | – | 0.01% | 468 |
|
|
2022
Q1 | $601K | Buy |
6,412
+745
| +13% | +$69.8K | 0.01% | 491 |
|
|
2021
Q4 | $483K | Buy |
5,667
+355
| +7% | +$30.3K | 0.01% | 567 |
|
|
2021
Q3 | $509K | Buy |
5,312
+171
| +3% | +$16.4K | 0.01% | 491 |
|
|
2021
Q2 | $500K | Sell |
5,141
-2
| -0% | -$195 | 0.01% | 479 |
|
|
2021
Q1 | $500K | Buy |
5,143
+762
| +17% | +$74.1K | 0.01% | 460 |
|
|
2020
Q4 | $420K | Sell |
4,381
-1,075
| -20% | -$103K | 0.01% | 459 |
|
|
2020
Q3 | $525K | Buy |
+5,456
| New | +$525K | 0.02% | 369 |
|